Key decision points in multiple sclerosis (MS) management would benefit from precision medicine—using information about an individual’s genomics, environment, and lifestyle, not just their signs and symptoms—to subtype their disease and make personalized decisions about their treatment.

Using machine learning, researchers in the Brigham Multiple Sclerosis Center and colleagues have developed a tool for predicting what the outcome of patients with recently diagnosed MS will be in 10 years.

Researchers at the Ann Romney Center for Neurologic Diseases at the Brigham, and colleagues have affirmed miR-92a as a powerful, clinically relevant target in multiple sclerosis and give preliminary information about the effects of inhibiting miR-92a in central nervous system autoimmune disease.

Researchers at Brigham and Women’s Hospital developed the Multiple Sclerosis Disease Activity (MSDA) Test, a multiprotein, serum-based biomarker assay for MS diagnosis, and have reported clinical validation of the assay.

The American Academy of Neurology (AAN) will hosts its 2024 annual meeting on April 13 – 18 in Denver, CO and virtually. Faculty from the Department of Neurology at Brigham and Women’s Hospital will join thousands of international colleagues in presenting their latest research at AAN 2024.

Serum biomarkers are becoming increasingly investigated for risk profiling in MS. Researchers at Brigham and Women’s Hospital have found that changes in two of them after treatment is stopped can signal impending disease activity.